0000950170-23-069417.txt : 20231211 0000950170-23-069417.hdr.sgml : 20231211 20231211161709 ACCESSION NUMBER: 0000950170-23-069417 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231207 FILED AS OF DATE: 20231211 DATE AS OF CHANGE: 20231211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanchez Ramiro CENTRAL INDEX KEY: 0001830326 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39311 FILM NUMBER: 231478342 MAIL ADDRESS: STREET 1: C/O CEREVELL THERAPEUTICS HOLDINGS INC. STREET 2: 131 DARTMOUTH STREET SUITE 502 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001805387 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 844-304-2048 MAIL ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II DATE OF NAME CHANGE: 20200303 4 1 ownership.xml 4 X0508 4 2023-12-07 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001830326 Sanchez Ramiro C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200 CAMBRIDGE MA 02141 false true false false Chief Medical Officer true Common Stock 2023-12-07 4 M false 10000 3.50 A 10000 D Common Stock 2023-12-07 4 S false 10000 41.37 D 0 D Stock Option (Right to Buy) 3.50 2023-12-07 4 M false 10000 0.00 D 2029-02-27 Common Stock 10000 548435 D These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person. 25% of the shares subject to this option vested and became exercisable on January 14, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. /s/ Mark Bodenrader, as Attorney-in-Fact 2023-12-11